Faron Pharmaceuticals Oy (FARN) Earnings Call Transcripts
Faron Pharmaceuticals Oy's Latest Earnings Call - June 15, 2026
In the second quarter of 2026, Faron Pharmaceuticals reported significant advancements in its BEXMAB trial for high-risk MDS, showcasing a complete remission rate of 45% and an overall response rate of 85% in treatment-naive patients. The duration of complete remission has improved to 16.1 months, up from 12 months previously reported, indicating strong efficacy. Management has confirmed that preparations for the Phase IIb BEXERA trial are on track, with the first patient expected to be enrolled in October 2026, signaling a positive outlook for future growth.
Reported metrics
| Metric | Value |
|---|---|
| Complete Remission Rate | 45% (beat) |
| Overall Response Rate | 85% (beat) |
| Duration of Complete Remission | 16.1 months (beat) |
| Adverse Events (Grade 3 or higher) | 32.7% (inline) |
| First Patient Enrollment for BEXERA Trial | October 2026 (positive) |
Guidance from management
Management confirmed that the preparations for the Phase IIb BEXERA trial are on track, with the first patient expected to be enrolled in October 2026. No changes to previous guidance were noted.
What management said
Next slide. Thank you, Mika. Very nice biomarker data, really, I would say, capturing and highlighting the effect of the bex has on the immune system and activating the immune system and activating also hematopoiesis in this, again, very frail patients. Next to over to our CMO, Dr. Bono on where are we with starting the upcoming Phase IIb.
Yes. Thank you, Petri. And opening up to Q&A as our Investor Relations starts getting in those stores in. I have a couple to start with and now that I have Mika here, we were actually so busy at the [indiscernible] conference, didn't have proper time to discuss with Mika that how do you see now bex in this field compared to others and how much excitement? To me, it felt that this is the readout that everybody will be...
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape and the need for clear differentiation of BEXMAB from existing therapies. There were also questions about the long-term sustainability of the response rates observed in the trial.
Main topics on the call
- Efficacy of BEXMAB Trial — The BEXMAB trial demonstrated a complete remission rate of 45% and an overall response rate of 85% in treatment-naive high-risk MDS patients. Management stated, "the responses continue to be maintained," highlighting the...
- Improved Duration of Complete Remission — The duration of complete remission has increased to 16.1 months, a notable improvement from the previously reported 12 months. This was emphasized by management as a critical metric for regulatory approval, stating, "the...
- Upcoming Phase IIb BEXERA Trial — Faron is set to initiate the Phase IIb BEXERA trial with first patient enrollment expected in October 2026. Dr. Bono noted, "we are on track to really have the first patients enrolled to the trial already in early Octobe...
- Safety Profile of BEXMAB — The safety profile of BEXMAB remains favorable, with no Grade 5 adverse events reported. Management stated, "the safety profile remains actually numbers very similar to earlier which is good news," reinforcing confidence...
Read the full Faron Pharmaceuticals Oy transcript (June 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy (FARN) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on AIM and is based in GB. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 28 calls on record spanning September 24, 2020 to June 15, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 28 Faron Pharmaceuticals Oy earnings call transcripts on record, spanning September 24, 2020 to June 15, 2026. Based on this history, Faron Pharmaceuticals Oy reports quarterly. The most recent call on file is dated June 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- FARN
- Exchange
- AIM
- Country
- GB
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 28
- First call
- September 24, 2020
- Most recent
- June 15, 2026
- Reporting cadence
- quarterly